Studymoderate evidence
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases.
Nature·June 10, 2026·PMID 42271063
Why it mattersChronic liver diseases like MASH and cholestatic disorders have limited therapies. Linafexor's pulsatile mechanism may overcome the efficacy and safety limitations of continuous FXR activation, offering a novel approach that could improve the therapeutic index in these conditions.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled